Proteus, Veolia Environnement partnering for water treatment

Nimes, France-based biotechnology company and Veolia Environnement have announced the signature of a collaboration agreement, demonstrating their commitment to associate their respective experience and know-how for the benefit of environmental care. In the framework of this agreement, both companies have already set common objectives including the development of innovative bio-processes for wastewater treatment...

NIMES, France, March 20, 2007 -- Proteus and Veolia Environnement have today announced the signature of a collaboration agreement, demonstrating their commitment to associate their respective experience and know-how for the benefit of environmental care. In the framework of this agreement, both companies have already set common objectives including the development of innovative bio-processes for wastewater treatment.

Proteus and Veolia share a common enthusiasm for this project. Environmental issues, especially those related to wastewater treatment, are a major challenge for the beginning century. Beyond their collaboration, the agreement between the companies highlights the complementary focus between Veolia's experience and prospective vision, and Protéus' know-how and innovative technologies for exploiting biodiversity resources.

Paris-based Veolia Environnement (www.veolia.com) is world leader in environmental services. With more than 300,000 employees the company has operations all around the world and provides tailored solutions to meet the needs of municipal and industrial customers in four complementary segments: water management, waste management, energy management and freight and passenger transportation. Veolia Environnement recorded revenue of €28.6 billion [US$38.1 billion] in 2006.

Proteus S.A. (www.proteus.fr), based in Nimes, France, is a leading biotechnology company specialized in the discovery, engineering and development of novel proteins and processes that meet industrial and therapeutic objectives. Since 1998, Proteus has been partnering with major life science industrial players. In 2006, the company strengthened its position in the life science and healthcare industry by creating two novel structures:
-- PSI: a division dedicated to supporting healthcare and life science companies in the optimization, development and production of their active proteins.
-- PCAS Biosolution SAS, a subsidiary co-owned with PCAS for the development and production of pharmaceutical molecules using a combination of chemistry and biocatalysis, known as chemo-biocatalysis.

---

Also see:
--- "London Borough selects Veolia Environmental Services: Southwark Council names it preferred bidder on 25-year private finance initiative for wastewater management contract"
--- "Kruger Inc. selects Norit X-Flow as alliance partner for UF membranes"

###

More in Environmental